Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
VolitionRx Limited - SIC # 3850 -
Ticker
Exchange
SIC #
Website
Latest Ticker
VNRX
NYSE American
3850
www.volition.com
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for VolitionRx Limited
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
- Feb 6th, 2025 1:30 pm
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025
- Feb 5th, 2025 2:15 pm
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis
- Jan 30th, 2025 1:30 pm
Volition Issues Business Review 2024
- Jan 8th, 2025 1:30 pm
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants
- Dec 12th, 2024 1:00 pm
Study shows Nu.Q® Lung Cancer Test differentiated malignant and benign nodules found by Low Dose CT screening
- Dec 10th, 2024 1:00 pm
VolitionRx Announces Pricing of up to $1.9 Million Registered Direct Offering
- Dec 6th, 2024 2:00 pm
VNRX: VolitionRx Reports 3Q 2024 results. Over 110,000 Nu.Q Canine Cancer tests have been sold. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR & Nu.Q NETs.
- Dec 4th, 2024 9:32 am
VolitionRX Ltd (VNRX) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...
- Nov 16th, 2024 7:02 am
VolitionRX: Q3 Earnings Snapshot
- Nov 15th, 2024 10:32 am
VolitionRx Limited Announces Third Quarter 2024 Financial Results and Business Update
- Nov 14th, 2024 9:10 pm
VolitionRx Limited Schedules Third Quarter 2024 Earnings Conference Call and Business Update
- Nov 8th, 2024 1:00 pm
Volition Appoints Timothy I. Still as Chairman
- Nov 6th, 2024 9:10 pm
Multiple studies show Nu.Q® NETs test could predict sepsis patients at risk of deteriorating
- Oct 31st, 2024 12:00 pm
Volition to share new 'NETs in sepsis management' data insights at upcoming webinar
- Oct 9th, 2024 12:00 pm
Volition hosts NETs in sepsis management symposium at ESICM Lives 2024
- Oct 3rd, 2024 12:00 pm
Volition Appoints Dr. Ethel Rubin as an Independent Director
- Sep 30th, 2024 8:10 pm
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
- Sep 20th, 2024 12:35 pm
Life Sciences Virtual Investor Forum Agenda Announced for September 19th
- Sep 16th, 2024 4:07 pm
Volition Hosts KOL Roundtable on Sepsis
- Sep 11th, 2024 12:00 pm
Scroll